PHARMACOKINETICS OF NIFURTIMOX IN CHRONIC-RENAL-FAILURE
| Author | dc.contributor.author | González Martin, G | |
| Author | dc.contributor.author | Thambo Becker, Sergio | es_CL |
| Author | dc.contributor.author | Paulos, Claudio | es_CL |
| Author | dc.contributor.author | Vásquez, I. | es_CL |
| Author | dc.contributor.author | Paredes, J. | es_CL |
| Admission date | dc.date.accessioned | 2011-06-08T15:43:02Z | |
| Available date | dc.date.available | 2011-06-08T15:43:02Z | |
| Publication date | dc.date.issued | 1992-06 | |
| Cita de ítem | dc.identifier.citation | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 42 (6): 671-674 | es_CL |
| Identifier | dc.identifier.issn | 0031-6970 | |
| Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/121254 | |
| General note | dc.description | Artículo de publicación ISI | es_CL |
| Abstract | dc.description.abstract | The pharmacokinetics of nifurtimox. a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC. The patients with chronic renal failure had a higher C(max) than the control subjects due to a change in systemic availability. An alternative explanation would bc that both thc distribution volume and thc clearance had changed. The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects. | es_CL |
| Lenguage | dc.language.iso | en | es_CL |
| Publisher | dc.publisher | SPRINGER VERLAG | es_CL |
| Keywords | dc.subject | NIFURTIMOX | es_CL |
| Título | dc.title | PHARMACOKINETICS OF NIFURTIMOX IN CHRONIC-RENAL-FAILURE | es_CL |
| Document type | dc.type | Artículo de revista |
Files in this item
This item appears in the following Collection(s)
-
Artículos de revistas
Artículos de revistas